This measure is an all-or-none composite of the number of patients following an ICD/CRT-D implant procedure who received prescriptions for all medications (Angiotensin-converting enzyme inhibitors (ACE-I)/ Angiotensin receptor blockers (ARB)/ Angiotensin receptor-neprilysin inhibitors (ARNI) and beta blockers) for which they are eligible at discharge and those patients with procedures that fulfill class I, IIa, or IIb guideline indications.
-
-
1.8 Level Of Analysis
-
1.14 Numerator
Generator patients: Who receive all medications for which they are eligible: ACE/ARB/ARNI prescribed at discharge (if eligible for ACE/ARB/ARNI as described in denominator) AND Beta blockers prescribed at discharge (if eligible for beta blockers as described in denominator), AND Whose procedures fulfill class I, IIa, or IIb guideline indications.
-
1.15 Denominator
All generator patients surviving hospitalization who meet the criteria for the individual metrics in the composite.
-
Exclusions
None.
-
OLD 1.12 MAT output not attachedAttached
-
Most Recent Endorsement ActivityPrevention and Population Health Spring 2023Initial Endorsement
-
StewardSteward Organization Email
-
-
-
Risk AdjustmentRisk adjustment approachOffRisk adjustment approachOffConceptual model for risk adjustmentOffConceptual model for risk adjustmentOff
-
-
-
6.1.2 Current or Planned Use(s)
-
Effective March 27, 2023, the National Quality Forum (NQF) is no longer the consensus-based entity (CBE) funded through the Centers for Medicare & Medicaid Services (CMS) National Consensus Development and Strategic Planning for Health Care Quality Measurement Contract. Battelle has been selected to oversee the endorsement & maintenance (E&M) of clinical quality and cost/resource use measures. Since the Spring 2023 cycle launched at NQF, measures submitted to this E&M cycle continued along the prior E&M protocols that were in place at time of the Spring 2023 “Intent to Submit.” Battelle took over the E&M work for the Spring 2023 cycle when developers and/or stewards submitted their full measure information, which for CBE #3748, the most recent measure specifications can be found here: https://p4qm.org/sites/default/files/2023-06/3748_epdi_quality_composite.zip
To close out this E&M cycle, Battelle published the Spring 2023 measures for pre-evaluation public commenting, convened the E&M standing committees for their measure evaluation meetings, launched the Spring 2023 post-comment period, convened the E&M committees for the post-comment meeting, convened the CSAC to render a final endorsement decision, and executed the appeals period.